Cyclomics has developed cutting-edge technology for detecting circulating tumor DNA using 3rd generation Nanopore sequencers, enabling fast, low-cost, point-of-care sequencing with nearly 100% accuracy to detect single ctDNA molecules. The company launched its services branch, expanding its technology and expertise into life sciences, biotechnology, genomics, and clinical diagnostics.
Cyborg Score Rationale
Cyclomics has a proprietary, published technology with significant academic backing, strategic partnerships with Oxford Nanopore, and demonstrated clinical applications. However, the failed acquisition attempt in early 2026 and private funding status limit near-term growth visibility and scale.
Top Insights
Accepted into Google Cloud Startup Program to support computational needs for big data and AI model training
Published NanoRCS technology in Genome Research showcasing enhanced genome-wide ctDNA sequencing for ultra-sensitive, cost-effective cancer detection
Acquisition discussions with GEDiCube stopped in early 2026, marking a significant strategic pivot
Established advisory board chaired by Joris Schuurmans with experienced members from molecular cancer diagnostics and life sciences investment
Named Competitors
Guardant Health — Leading ctDNA-based cancer detection and monitoring platform
Foundation Medicine — Precision oncology genomics for cancer diagnosis and treatment
GRAIL (Galleri) — Multi-cancer early detection blood test
Tempus — AI-powered genomics and molecular diagnostics